ResMed Closes Sale of MatrixCare and Receives Analyst Upgrades Amid Strategic Refocus

ResMed (NYSE: RMD) completed the sale of its MatrixCare software business to Frazier Healthcare Partners on August 31, 2026. The divestiture, valued at $490 million in cash, aligns with ResMed’s broader strategy to sharpen its focus on sleep health, breathing health, and connected home-based care. MatrixCare, which provides software services to over 15,000 healthcare providers across skilled nursing, senior living, and home health settings, will continue operations unchanged under its current structure until the deal closes, expected in ResMed’s fiscal Q1 2027. Meanwhile, proceeds from the transaction are earmarked for general corporate purposes and shareholder returns, including accelerated share repurchases.

The sale had previously been announced on July 7, 2026, when ResMed entered into the agreement with Frazier Healthcare Partners. As of that announcement, the business remained under ResMed’s operations with no disruptions to customer support or service. Financial disclosures indicate that MatrixCare generated approximately $220 million in revenue and $55 million in operating profit in fiscal 2026, underscoring its significance within ResMed’s Residential Care Software segment. The divestiture represented a deliberate portfolio realignment that enables the company to reallocate resources to its higher-growth segments.

In a sign of growing investor confidence, KeyBanc upgraded its rating on ResMed to ‘Overweight’ and raised its 12-month price target from $255 to $267. The firm cited conviction in ResMed’s fiscal year 2027 outlook and management’s credible execution on its long-term 2030 strategy. KeyBanc noted that fully understanding and managing valuation overhangs, along with the company’s strong balance sheet and free cash flow, supported the optimistic outlook.

Why This Matters

The successful divestment of MatrixCare marks a strategic pivot, reinforcing ResMed’s core competence in medical devices, digital therapeutics, and connected health platforms. By shedding a slower-growth software business, ResMed can concentrate on innovation in its therapy device ecosystem, including sleep apnea solutions and respiratory-care offerings.

The timing of KeyBanc’s price target increase reflects the broader market’s favorable reception of this portfolio adjustment. Investors appear to reward clarity of purpose and disciplined capital allocation, especially given ResMed’s demonstrated ability to return value to shareholders through repurchases and dividends.

What to Watch Next

• Integration of proceeds from the MatrixCare sale—will ResMed prioritize debt reduction, reinvest in R&D, or commit further to shareholder returns?
• Progress on closing the deal and any regulatory feedback that could affect the timeline or terms.
• Updates on product rollouts or expansions in ResMed’s core segments, especially as capital and focus shift following the divestiture.
• Market response in post-sale earnings reports and whether FY27 guidance reflects the financial benefit of the divestiture.